Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 8214541, 15 pages
https://doi.org/10.1155/2017/8214541
Review Article

Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective

1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
2Cardiovascular Disease Centre, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
3School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
4Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China

Correspondence should be addressed to Yue Liu; moc.liamtoh@traeheuyuil and Shuzheng Lyu; nc.moc.liamdem@gnehzuhs

Received 13 July 2017; Revised 4 September 2017; Accepted 13 September 2017; Published 24 October 2017

Academic Editor: Kota V. Ramana

Copyright © 2017 Jinfan Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Falcão-Pires and A. F. Leite-Moreira, “Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment,” Heart Failure Reviews, vol. 17, no. 3, pp. 325–344, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Miki, S. Yuda, H. Kouzu, and T. Miura, “Diabetic cardiomyopathy: pathophysiology and clinical features,” Heart Failure Reviews, vol. 18, no. 2, pp. 149–166, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Li, T. Casteels, T. Frogne et al., “Artemisinins target GABAA receptor signaling and impair α cell identity,” Cell, vol. 168, no. 1-2, pp. 86–100.e15, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Cosson and J. P. Kevorkian, “Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy?” Diabetes & Metabolism, vol. 29, no. 5, pp. 455–466, 2003. View at Publisher · View at Google Scholar
  5. N. Amaral and D. O. Okonko, “Metabolic abnormalities of the heart in type II diabetes,” Diabetes and Vascular Disease Research, vol. 12, no. 4, pp. 239–248, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Taegtmeyer, P. McNulty, and M. E. Young, “Adaptation and maladaptation of the heart in diabetes: Part I: general concepts,” Circulation, vol. 105, no. 14, pp. 1727–1733, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. E. Young, P. McNulty, and H. Taegtmeyer, “Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms,” Circulation, vol. 105, no. 15, pp. 1861–1870, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Y. Zeng, X. Chen, S. R. Chen et al., “Upregulation of Nox4 promotes angiotensin II-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression,” Canadian Journal of Cardiology, vol. 29, no. 10, pp. 1310–1319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Sirker, M. Zhang, C. Murdoch, and A. M. Shah, “Involvement of NADPH oxidases in cardiac remodelling and heart failure,” American Journal of Nephrology, vol. 27, no. 6, pp. 649–660, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. G. Duncan, “Mitochondrial dysfunction in diabetic cardiomyopathy,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1813, no. 7, pp. 1351–1359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Lebeche, A. J. Davidoff, and R. J. Hajjar, “Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy,” Nature Clinical Practice Cardiovascular Medicine, vol. 5, no. 11, pp. 715–724, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Y. Zhao, S. J. Hu, J. Li, Y. Mou, B. P. Chen, and Q. Xia, “Decreased cardiac sarcoplasmic reticulum Ca2+ −ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats,” Journal of Physiology and Biochemistry, vol. 62, no. 1, pp. 1–8, 2006. View at Publisher · View at Google Scholar
  13. X. Jiang, W. Liu, J. Deng et al., “Polydatin protects cardiac function against burn injury by inhibiting sarcoplasmic reticulum Ca2+ leak by reducing oxidative modification of ryanodine receptors,” Free Radical Biology & Medicine, vol. 60, pp. 292–299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Yan, X. Luo, Y. Li et al., “Effects of advanced glycation end products on calcium handling in cardiomyocytes,” Cardiology, vol. 129, no. 2, pp. 75–83, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. L. M. Buja and D. Vela, “Cardiomyocyte death and renewal in the normal and diseased heart,” Cardiovascular Pathology, vol. 17, no. 6, pp. 349–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Xie, C. He, and M. H. Zou, “AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy,” Autophagy, vol. 7, no. 10, pp. 1254-1255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Xie, K. Lau, B. Eby et al., “Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice,” Diabetes, vol. 60, no. 6, pp. 1770–1778, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Zhao, L. Zhang, Y. Qiao et al., “Heme oxygenase-1 prevents cardiac dysfunction in streptozotocin-diabetic mice by reducing inflammation, oxidative stress, apoptosis and enhancing autophagy,” PLoS One, vol. 8, no. 9, article e75927, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Hou, Z. Hu, H. Xu et al., “Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway,” Cardiovascular Diabetology, vol. 13, no. 1, p. 78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Palomer, L. Salvadó, E. Barroso, and M. Vázquez-Carrera, “An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy,” International Journal of Cardiology, vol. 168, no. 4, pp. 3160–3172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Wang, L. Ding, H. Ji, Z. Xu, Q. Liu, and Y. Zheng, “The role of p38 MAPK in the development of diabetic cardiomyopathy,” International Journal of Molecular Sciences, vol. 17, no. 7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Min, Z. W. Bin, Z. B. Quan, Z. J. Hui, and F. G. Sheng, “The signal transduction pathway of PKC/NF-κB/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats,” Cardiovascular Diabetology, vol. 8, no. 1, p. 8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Van Linthout, A. Riad, N. Dhayat et al., “Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy,” Diabetologia, vol. 50, no. 9, pp. 1977–1986, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Y. Ko, I. H. Lin, T. M. Shieh et al., “Cell hypertrophy and MEK/ERK phosphorylation are regulated by glyceraldehyde-derived AGEs in cardiomyocyte H9c2 cells,” Cell Biochemistry and Biophysics, vol. 66, no. 3, pp. 537–544, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Tanaka, M. Honda, and T. Takabatake, “Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 676–685, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Tang, W. Zhang, H. Lin, H. Jiang, H. Dai, and Y. Zhang, “High glucose promotes the production of collagen types I and III by cardiac fibroblasts through a pathway dependent on extracellular-signal-regulated kinase 1/2,” Molecular and Cellular Biochemistry, vol. 301, no. 1-2, pp. 109–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Zhang, Z. Huang, J. Gu et al., “Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway,” Diabetologia, vol. 58, no. 8, pp. 1937–1948, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Xu, J. Sun, Q. Tong et al., “The role of ERK1/2 in the development of diabetic cardiomyopathy,” International Journal of Molecular Sciences, vol. 17, no. 12, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. K. H. Tsai, W. J. Wang, C. W. Lin et al., “NADPH oxidase-derived superoxide anion-induced apoptosis is mediated via the JNK-dependent activation of NF-κB in cardiomyocytes exposed to high glucose,” Journal of Cellular Physiology, vol. 227, no. 4, pp. 1347–1357, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. M. Jeon, “Regulation and function of AMPK in physiology and diseases,” Experimental & Molecular Medicine, vol. 48, no. 7, article e245, 2016. View at Publisher · View at Google Scholar
  31. S. M. Cabarcas, E. M. Hurt, and W. L. Farrar, “Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease,” Current Molecular Medicine, vol. 10, no. 8, pp. 744–755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Woods, S. R. Johnstone, K. Dickerson et al., “LKB1 is the upstream kinase in the AMP-activated protein kinase cascade,” Current Biology, vol. 13, no. 22, pp. 2004–2008, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Woods, K. Dickerson, R. Heath et al., “Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells,” Cell Metabolism, vol. 2, no. 1, pp. 21–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. B. F. Holmes, D. P. Sparling, A. L. Olson, W. W. Winder, and G. L. Dohm, “Regulation of muscle GLUT4 enhancer factor and myocyte enhancer factor 2 by AMP-activated protein kinase,” American Journal of Physiology - Endocrinology and Metabolism, vol. 289, no. 6, pp. E1071–E1076, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. D. D. Habets, W. A. Coumans, M. El Hasnaoui et al., “Crucial role for LKB1 to AMPKα2 axis in the regulation of CD36-mediated long-chain fatty acid uptake into cardiomyocytes,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1791, no. 3, pp. 212–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. J. Garton, D. G. Campbell, D. Carling, D. G. Hardie, R. J. Colbran, and S. J. Yeaman, “Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism,” European Journal of Biochemistry, vol. 179, no. 1, pp. 249–254, 1989. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Salminen, J. Ojala, J. Huuskonen, A. Kauppinen, T. Suuronen, and K. Kaarniranta, “Interaction of aging-associated signaling cascades: Inhibition of NF-κB signaling by longevity factors FoxOs and SIRT1,” Cellular and Molecular Life Sciences, vol. 65, no. 7-8, pp. 1049–1058, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Salminen, J. M. Hyttinen, and K. Kaarniranta, “AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan,” Journal of Molecular Medicine, vol. 89, no. 7, pp. 667–676, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Egan, J. Kim, R. J. Shaw, and K. L. Guan, “The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR,” Autophagy, vol. 7, no. 6, pp. 643-644, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. R. J. Shaw, “LKB1 and AMP-activated protein kinase control of mTOR signalling and growth,” Acta Physiologica, vol. 196, no. 1, pp. 65–80, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. C. He, H. Zhu, H. Li, M. H. Zou, and Z. Xie, “Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes,” Diabetes, vol. 62, no. 4, pp. 1270–1281, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. H. Zou and Z. Xie, “Regulation of interplay between autophagy and apoptosis in the diabetic heart: new role of AMPK,” Autophagy, vol. 9, no. 4, pp. 624-625, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. B. N. Finck, J. J. Lehman, T. C. Leone et al., “The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus,” Journal of Clinical Investigation, vol. 109, no. 1, pp. 121–130, 2002. View at Publisher · View at Google Scholar
  44. E. M. Burkart, N. Sambandam, X. Han et al., “Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart,” Journal of Clinical Investigation, vol. 117, no. 12, pp. 3930–3939, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Botta, I. Laher, J. Beam et al., “Short term exercise induces PGC-1α, ameliorates inflammation and increases mitochondrial membrane proteins but fails to increase respiratory enzymes in aging diabetic hearts,” PLoS One, vol. 8, no. 8, article e70248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Wang, Y. Bei, Y. Lu et al., “Exercise prevents cardiac injury and improves mitochondrial biogenesis in advanced diabetic cardiomyopathy with PGC-1a and Akt activation,” Cellular Physiology and Biochemistry, vol. 35, no. 6, pp. 2159–2168, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. N. E. Buroker, J. Barboza, and J. Y. Huang, “The IκBα gene is a peroxisome proliferator-activated receptor cardiac target gene,” FEBS Journal, vol. 276, no. 12, pp. 3247–3255, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Planavila, R. Rodríguez-Calvo, M. Jové et al., “Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes,” Cardiovascular Research, vol. 65, no. 4, pp. 832–841, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Asakawa, H. Takano, T. Nagai et al., “Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo,” Circulation, vol. 105, no. 10, pp. 1240–1246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Lan, J. M. Cacicedo, N. Ruderman, and Y. Ido, “SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation,” Journal of Biological Chemistry, vol. 283, no. 41, pp. 27628–27635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. W. Pan, H. Yu, S. Huang, and P. Zhu, “Resveratrol protects against TNF-α-induced injury in human umbilical endothelial cells through promoting sirtuin-1-induced repression of NF-KB and p38 MAPK,” PLoS One, vol. 11, no. 1, article e0147034, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Sulaiman, M. J. Matta, N. R. Sunderesan, M. P. Gupta, M. Periasamy, and M. Gupta, “Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy,” American Journal of Physiology - Heart and Circulatory Physiology, vol. 298, no. 3, pp. H833–H843, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Karbasforooshan and G. Karimi, “The role of SIRT1 in diabetic cardiomyopathy,” Biomedicine & Pharmacotherapy, vol. 90, pp. 386–392, 2017. View at Publisher · View at Google Scholar
  54. X. He, H. Kan, L. Cai, and Q. Ma, “Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes,” Journal of Molecular and Cellular Cardiology, vol. 46, no. 1, pp. 47–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Yu, Y. Liu, B. Zhang, Y. Shi, L. Cui, and X. Zhao, “Inhibiting microRNA-144 abates oxidative stress and reduces apoptosis in hearts of streptozotocin-induced diabetic mice,” Cardiovascular Pathology, vol. 24, no. 6, pp. 375–381, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Jeyabal, R. A. Thandavarayan, D. Joladarashi et al., “MicroRNA-9 inhibits hyperglycemia-induced pyroptosis in human ventricular cardiomyocytes by targeting ELAVL1,” Biochemical and Biophysical Research Communications, vol. 471, no. 4, pp. 423–429, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Zheng, J. Ma, Y. Yu et al., “Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice,” Diabetologia, vol. 58, no. 8, pp. 1949–1958, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Liu, W. Li, M. Xu, H. Huang, J. Wang, and X. Chen, “Micro-RNA 21 targets dual specific phosphatase 8 to promote collagen synthesis in high glucose-treated primary cardiac fibroblasts,” Canadian Journal of Cardiology, vol. 30, no. 12, pp. 1689–1699, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. G. B. Singh, S. K. Raut, S. Khanna et al., “MicroRNA-200c modulates DUSP-1 expression in diabetes-induced cardiac hypertrophy,” Molecular and Cellular Biochemistry, vol. 424, no. 1-2, pp. 1–11, 2017. View at Publisher · View at Google Scholar · View at Scopus
  60. S. K. Raut, A. Kumar, G. B. Singh et al., “miR-30c mediates upregulation of Cdc42 and Pak1 in diabetic cardiomyopathy,” Cardiovascular Therapeutics, vol. 33, no. 3, pp. 89–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. X. Li, N. Du, Q. Zhang et al., “MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy,” Cell Death and Disease, vol. 5, article e1479, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Qiu and P. N. Kao, “Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f,” Drugs in R&D, vol. 4, no. 1, pp. 1–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Li, K. Lu, Y. Wang et al., “Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression,” Biochemical and Biophysical Research Communications, vol. 485, no. 1, pp. 69–75, 2017. View at Publisher · View at Google Scholar
  64. H. L. Wen, Z. S. Liang, R. Zhang, and K. Yang, “Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy,” Cardiovascular Diabetology, vol. 12, no. 1, p. 50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. Liang, S. Leo, H. Wen, M. Ouyang, W. Jiang, and K. Yang, “Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats,” BMC Cardiovascular Disorders, vol. 15, p. 42, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. X. Guo, M. Xue, C. J. Li et al., “Protective effects of triptolide on TLR4 mediated autoimmune and inflammatory response induced myocardial fibrosis in diabetic cardiomyopathy,” Journal of Ethnopharmacology, vol. 193, pp. 333–344, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. V. Soetikno, K. Watanabe, F. R. Sari et al., “Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-β1 activity in streptozotocin-induced type I diabetic rats,” Molecular Nutrition & Food Research, vol. 55, no. 11, pp. 1655–1665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. V. Soetikno, F. R. Sari, V. Sukumaran et al., “Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC-MAPK signaling pathway,” European Journal of Pharmaceutical Sciences, vol. 47, no. 3, pp. 604–614, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Pan, Y. Wang, Y. Zhao et al., “Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy,” Diabetes, vol. 63, no. 10, pp. 3497–3511, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Wang, S. Zhou, W. Sun et al., “Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression,” American Journal of Physiology - Endocrinology and Metabolism, vol. 306, no. 11, pp. E1239–E1247, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Fitzl, R. Martin, D. Dettmer, V. Hermsdorf, H. Drews, and K. Welt, “Protective effects of Gingko biloba extract EGb 761 on myocardium of experimentally diabetic rats. I: ultrastructural and biochemical investigation on cardiomyocytes,” Experimental and Toxicologic Pathology, vol. 51, no. 3, pp. 189–198, 1999. View at Publisher · View at Google Scholar
  72. K. Welt, J. Weiss, S. Koch, and G. Fitzl, “Protective effects of Ginkgo biloba extract EGb 761 on the myocardium of experimentally diabetic rats. II. Ultrastructural and immunohistochemical investigation on microvessels and interstitium,” Experimental and Toxicologic Pathology, vol. 51, no. 3, pp. 213–222, 1999. View at Publisher · View at Google Scholar
  73. G. Fitzl, K. Welt, R. Martin et al., “The influence of hypoxia on the myocardium of experimentally diabetic rats with and without protection by Ginkgo biloba extract. I. Ultrastructural and biochemical investigations on cardiomyocytes,” Experimental and Toxicologic Pathology, vol. 52, no. 5, pp. 419–430, 2000. View at Publisher · View at Google Scholar
  74. K. Welt, G. Fitzl, and A. Schepper, “Experimental hypoxia of STZ-diabetic rat myocardium and protective effects of Ginkgo biloba extract. II. Ultrastructural investigation of microvascular endothelium,” Experimental and Toxicologic Pathology, vol. 52, no. 6, pp. 503–512, 2001. View at Publisher · View at Google Scholar
  75. A. S. Saini, R. Taliyan, and P. L. Sharma, “Protective effect and mechanism of Ginkgo biloba extract-EGb 761 on STZ-induced diabetic cardiomyopathy in rats,” Pharmacognosy Magazine, vol. 10, no. 38, pp. 172–178, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. H. C. Su, L. M. Hung, and J. K. Chen, “Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats,” American Journal of Physiology - Endocrinology and Metabolism, vol. 290, no. 6, pp. E1339–E1346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Turan, E. Tuncay, and G. Vassort, “Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies,” Journal of Bioenergetics and Biomembranes, vol. 44, no. 2, pp. 281–296, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. S. V. Penumathsa, M. Thirunavukkarasu, L. Zhan et al., “Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium,” Journal of Cellular and Molecular Medicine, vol. 12, no. 6A, pp. 2350–2361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Guo, Q. Yao, Z. Ke, H. Chen, J. Wu, and C. Liu, “Resveratrol attenuates high glucose-induced oxidative stress and cardiomyocyte apoptosis through AMPK,” Molecular and Cellular Endocrinology, vol. 412, pp. 85–94, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. A. S. Yar, S. Menevse, and E. Alp, “The effects of resveratrol on cyclooxygenase-1 and -2, nuclear factor kappa beta, matrix metalloproteinase-9, and sirtuin 1 mRNA expression in hearts of streptozotocin-induced diabetic rats,” Genetics and Molecular Research, vol. 10, no. 4, pp. 2962–2975, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. W. Chen, Y. M. Li, and M. H. Yu, “Effects of astragalus polysaccharides on chymase, angiotensin-converting enzyme and angiotensin II in diabetic cardiomyopathy in hamsters,” Journal of International Medical Research, vol. 35, no. 6, pp. 873–877, 2007. View at Publisher · View at Google Scholar
  82. W. Chen, M. H. Yu, Y. M. Li, W. J. Chen, and Y. P. Xia, “Beneficial effects of astragalus polysaccharides treatment on cardiac chymase activities and cardiomyopathy in diabetic hamsters,” Acta Diabetologica, vol. 47, Supplement 1, pp. 35–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. W. Chen, Y. M. Li, and M. H. Yu, “Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation,” Journal of Diabetes and its Complications, vol. 24, no. 3, pp. 199–208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. W. Chen, Y. P. Xia, W. J. Chen, M. H. Yu, Y. M. Li, and H. Y. Ye, “Improvement of myocardial glycolipid metabolic disorder in diabetic hamster with astragalus polysaccharides treatment,” Molecular Biology Reports, vol. 39, no. 7, pp. 7609–7615, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Sun, S. Yang, M. Dai et al., “The effect of astragalus polysaccharides on attenuation of diabetic cardiomyopathy through inhibiting the extrinsic and intrinsic apoptotic pathways in high glucose -stimulated H9C2 cells,” BMC Complementary and Alternative Medicine, vol. 17, no. 1, p. 310, 2017. View at Publisher · View at Google Scholar
  86. J. Yu, J. Fei, J. Azad, M. Gong, Y. Lan, and G. Chen, “Myocardial protection by Salvia miltiorrhiza injection in streptozotocin-induced diabetic rats through attenuation of expression of thrombospondin-1 and transforming growth factor-β1,” Journal of International Medical Research, vol. 40, no. 3, pp. 1016–1024, 2012. View at Publisher · View at Google Scholar
  87. S. H. Lo, C. T. Hsu, H. S. Niu, C. S. Niu, J. T. Cheng, and Z. C. Chen, “Cryptotanshinone inhibits STAT3 signaling to alleviate cardiac fibrosis in type 1-like diabetic rats,” Phytotherapy Research, vol. 31, no. 4, pp. 638–646, 2017. View at Publisher · View at Google Scholar
  88. N. Rani, S. Bharti, J. Bhatia, T. C. Nag, R. Ray, and D. S. Arya, “Chrysin, a PPAR-γ agonist improves myocardial injury in diabetic rats through inhibiting AGE-RAGE mediated oxidative stress and inflammation,” Chemico-Biological Interactions, vol. 250, pp. 59–67, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Rani, S. Bharti, J. Bhatia et al., “Inhibition of TGF-β by a novel PPAR-γ agonist, chrysin, salvages β-receptor stimulated myocardial injury in rats through MAPKs-dependent mechanism,” Nutrition & Metabolism, vol. 12, p. 11, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Zhang, Q. Shen, Y. Chen et al., “Myricitrin alleviates oxidative stress-induced inflammation and apoptosis and protects mice against diabetic cardiomyopathy,” Scientific Reports, vol. 7, article 44239, 2017. View at Publisher · View at Google Scholar
  91. U. B. Mahajan, G. Chandrayan, C. R. Patil et al., “The protective effect of apigenin on myocardial injury in diabetic rats mediating activation of the PPAR-γ pathway,” International Journal of Molecular Sciences, vol. 18, no. 4, 2017. View at Publisher · View at Google Scholar
  92. X. Sun, R. C. Chen, Z. H. Yang et al., “Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis,” Food and Chemical Toxicology, vol. 63, pp. 221–232, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. Y. Yu and G. Zheng, “Troxerutin protects against diabetic cardiomyopathy through NF-κB/AKT/IRS1 in a rat model of type 2 diabetes,” Molecular Medicine Reports, vol. 15, no. 6, pp. 3473–3478, 2017. View at Publisher · View at Google Scholar
  94. Y. O. Agrawal, P. K. Sharma, B. Shrivastava, D. S. Arya, and S. N. Goyal, “Hesperidin blunts streptozotocin-isoproternol induced myocardial toxicity in rats by altering of PPAR-γ receptor,” Chemico-Biological Interactions, vol. 219, pp. 211–220, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Zhang, Z. Yang, S. Z. Xiang et al., “Nobiletin attenuates cardiac dysfunction, oxidative stress, and inflammatory in streptozotocin: induced diabetic cardiomyopathy,” Molecular and Cellular Biochemistry, vol. 417, no. 1-2, pp. 87–96, 2016. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Chen, R. Guo, H. Yan et al., “Naringin inhibits ROS-activated MAPK pathway in high glucose-induced injuries in H9c2 cardiac cells,” Basic & Clinical Pharmacology & Toxicology, vol. 114, no. 4, pp. 293–304, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Zhang, L. Zhang, Y. Zhang, J. J. Xu, L. L. Sun, and S. Z. Li, “The protective role of liquiritin in high fructose-induced myocardial fibrosis via inhibiting NF-κB and MAPK signaling pathway,” Biomedicine & Pharmacotherapy, vol. 84, pp. 1337–1349, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. X. W. Xie, “Liquiritigenin attenuates cardiac injury induced by high fructose-feeding through fibrosis and inflammation suppression,” Biomedicine & Pharmacotherapy, vol. 86, pp. 694–704, 2017. View at Publisher · View at Google Scholar
  99. J. Zhao, T. T. Cao, J. Tian et al., “Shengmai san ameliorates myocardial dysfunction and fibrosis in diabetic db/db mice,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 4621235, 9 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  100. Q. Ni, J. Wang, E. Q. Li et al., “Study on the protective effect of the mixture of Shengmai powder and Danshen decoction on the myocardium of diabetic cardiomyopathy in the rat model,” Chinese Journal of Integrative Medicine, vol. 17, no. 2, pp. 116–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Sen, S. Chen, Y. Wu, B. Feng, E. K. Lui, and S. Chakrabarti, “Preventive effects of North American ginseng (Panax quinquefolius) on diabetic retinopathy and cardiomyopathy,” Phytotherapy Research, vol. 27, no. 2, pp. 290–298, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. J. N. Gu, J. Niu, Z. F. Pi, H. Yue, S. S. Wu, and S. Y. Liu, “Study on the mechanism of total saponins of panax ginseng in treatment of diabetic cardiomyopathy in rat assessed by urine metabonomics,” Chinese Journal of Analytical Chemistry, vol. 41, no. 3, pp. 371–376, 2013, [Article in Chinese]. View at Google Scholar
  103. H. T. Yu, J. Zhen, B. Pang, J. N. Gu, and S. S. Wu, “Ginsenoside Rg1 ameliorates oxidative stress and myocardial apoptosis in streptozotocin-induced diabetic rats,” Journal of Zhejiang University-Science B, vol. 16, no. 5, pp. 344–354, 2015. View at Publisher · View at Google Scholar · View at Scopus
  104. Z. Xu, S. Wang, H. Ji et al., “Broccoli sprout extract prevents diabetic cardiomyopathy via Nrf2 activation in db/db T2DM mice,” Science Reports, vol. 6, article 30252, 2016. View at Publisher · View at Google Scholar · View at Scopus
  105. Z. Zhang, D. Zhang, M. Dou, Z. Li, J. Zhang, and X. Zhao, “Dendrobium officinale Kimura et Migo attenuates diabetic cardiomyopathy through inhibiting oxidative stress, inflammation and fibrosis in streptozotocin-induced mice,” Biomedicine & Pharmacotherapy, vol. 84, pp. 1350–1358, 2016. View at Publisher · View at Google Scholar · View at Scopus
  106. W. Yu, W. Zha, S. Guo, H. Cheng, J. Wu, and C. Liu, “Flos Puerariae extract prevents myocardial apoptosis via attenuation oxidative stress in streptozotocin-induced diabetic mice,” PLoS One, vol. 9, no. 5, article e98044, 2014. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Hou, D. Zheng, G. Fung et al., “Mangiferin suppressed advanced glycation end products (AGEs) through NF-κB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats,” Canadian Journal of Physiology and Pharmacology, vol. 94, no. 3, pp. 332–340, 2016. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Xi, G. Zhou, X. Zhang, W. Zhang, L. Cai, and C. Zhao, “Protective effect of total aralosides of Aralia elata (Miq) Seem (TASAES) against diabetic cardiomyopathy in rats during the early stage, and possible mechanisms,” Experimental and Molecular Medicine, vol. 41, no. 8, pp. 538–547, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Duan, G. Wei, C. Guo et al., “Aralia taibaiensis protects cardiac myocytes against high glucose-induced oxidative stress and apoptosis,” The American Journal of Chinese Medicine, vol. 43, no. 6, pp. 1159–1175, 2015. View at Publisher · View at Google Scholar · View at Scopus
  110. W. Chang, M. Zhang, J. Li et al., “Berberine improves insulin resistance in cardiomyocytes via activation of 5-adenosine monophosphate-activated protein kinase,” Metabolism, vol. 62, no. 8, pp. 1159–1167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. W. Chang, M. Zhang, Z. Meng et al., “Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells,” European Journal of Pharmacology, vol. 769, pp. 55–63, 2015. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Shen, X. Li, T. Zhou et al., “Shensong Yangxin capsule prevents diabetic myocardial fibrosis by inhibiting TGF-β1/Smad signaling,” Journal of Ethnopharmacology, vol. 157, pp. 161–170, 2014. View at Publisher · View at Google Scholar · View at Scopus